In situ covalently cross-linked PEG hydrogel for ocular drug delivery applications.
Avastin(®) has been clinically proved to be effective in the treatment of intraocular neovascularization diseases. However, the short half-life of Avastin(®) need frequent administration to maintain its therapeutic efficiency. In this paper, we attempted to develop an in situ PEG hydrogels with great biocompatibility for sustained release of Avastin(®) to inhibit the corneal neovascularization. PEG hydrogels was formed via thiol-maleimide reaction using 4-arm PEG-Mal and 4-arm PEG-SH. The transparent hydrogel was rapidly formed under physiological conditions. By varying the concentration of 4-arm PEG-SH, PEG hydrogel with different gelling time, pore size, swelling ratio and mechanical property could be obtained. In vitro cytotoxicity indicated that the developed PEG hydrogel had no apparent cytotoxicity on L-929 cells after 7 days of incubation. In vitro release study showed the encapsulated Avastin(®) was sustained release from PEG hydrogels within a period of 14 days study. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis further confirmed that the released Avastin(®) did not undergo apparent hydrolysis within 14 days. As a conclusion, we could conclude that the developed PEG hydrogels as an injectable hydrogels might be suitable for extended Avastin(®) release to treat the corneal neovascularization.
Institute of Biomedical Engineering, School of Ophthalmology & Optometry and Eye hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou 325027, PR China.
Jing
J
Yu
Institute of Biomedical Engineering, School of Ophthalmology & Optometry and Eye hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou 325027, PR China.
Xu
X
Xu
Institute of Biomedical Engineering, School of Ophthalmology & Optometry and Eye hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou 325027, PR China; Wenzhou Institute of Biomaterials and Engineering, Wenzhou 325035, PR China.
FuLin
F
Yao
Institute of Biomedical Engineering, School of Ophthalmology & Optometry and Eye hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou 325027, PR China; Wenzhou Institute of Biomaterials and Engineering, Wenzhou 325035, PR China.
Zichao
Z
Luo
Institute of Biomedical Engineering, School of Ophthalmology & Optometry and Eye hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou 325027, PR China.
Ling
L
Jin
Institute of Biomedical Engineering, School of Ophthalmology & Optometry and Eye hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou 325027, PR China.
BinBin
B
Xie
Institute of Biomedical Engineering, School of Ophthalmology & Optometry and Eye hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou 325027, PR China.
Shuai
S
Shi
Institute of Biomedical Engineering, School of Ophthalmology & Optometry and Eye hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou 325027, PR China.
Huixiang
H
Ma
Institute of Biomedical Engineering, School of Ophthalmology & Optometry and Eye hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou 325027, PR China. Electronic address: lixingyi_1984@163.com.
XingYi
X
Li
Institute of Biomedical Engineering, School of Ophthalmology & Optometry and Eye hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou 325027, PR China.
Hao
H
Chen
D060433:Administration, Ophthalmic; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000737:chemistry*; D000068258:Bevacizumab; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D016503:Drug Delivery Systems; D020100:Hydrogels / Q000008:administration & dosage / Q000737:chemistry*; D008301:Maleimides / Q000737:chemistry; D051379:Mice; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000737:chemistry*; D012212:Rheology; D013438:Sulfhydryl Compounds / Q000737:chemistry
D061067:Antibodies, Monoclonal, Humanized; D020100:Hydrogels; D008301:Maleimides; D013438:Sulfhydryl Compounds; C043592:maleimide; D000068258:Bevacizumab; D011092:Polyethylene Glycols
Avastin; Corneal neovascularization; PEG hydrogel; Sustained release